Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this report, we found a rare case of RCC with a fusion between 5' EWSR1 and 3' TFE3.
|
31774608 |
2020 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ten patients with RBM10-TFE3 RCC aged 31-71 years were investigated.
|
30908700 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To broaden the spectrum of Xp11 neoplasms, we investigated a novel tumor exhibiting morphologies overlapping Xp11.2 translocation/TFE3 rearrangement-associated RCC and the mesenchymal counterpart with melanocytic differentiation by immunohistochemistry, fluorescence in situ hybridization (FISH) and RNA sequencing, as well as literature review.
|
31277953 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis was TFE3/Xp11.2 translocation RCC.
|
28478739 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
|
30787990 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual mTORC1/2 inhibition suppresses Akt/mTOR signaling more effectively than selective mTORC1 inhibition and demonstrates in vivo preclinical efficacy against TFE3-fusion renal cell carcinoma.
|
31519159 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Transcription factor E3 (TFE3) is a useful marker for tumors with Xp11.2 translocation, including alveolar soft part sarcoma and renal cell carcinoma.
|
31788112 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Xp11.2 translocation renal cell carcinoma (Xp11tRCC) is a subtype of renal cell carcinoma (RCC) characterized by chromosomal rearrangement of the region harboring the transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3).
|
31153695 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the 27 renal cell carcinomas with TFE3 strong positive immunostaining, 20 cases were diagnosed as Xp11 translocation renal cell carcinoma, and seven cases were diagnosed as clear cell renal cell carcinoma.
|
31175325 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Magnetic resonance imaging findings of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in adults: a pilot study.
|
30019296 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The KAT6A-TFE3 renal cell carcinoma demonstrated typical morphological features of TFE3/Xp11 renal cell carcinoma including papillae, eosinophilic cytoplasm with focal clearing and abundant psammoma bodies.
|
30622287 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, the subtyping process can be more complex in some cases: differential diagnosis (CCRCC or TFE3 TRCC, PRCC or TFE3 TRCC, oncocytic tumors corresponding to ChRCC or oncocytoma), molecular confirmation (TFEB TRCC) and unclassified RCC.
|
31437522 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TFE3-RCC mouse provides a preclinical <i>in vivo</i> model for the development of new biomarkers and targeted therapeutics for patients affected with this aggressive form of RCC.
|
31043488 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The TCGA data set of renal cell carcinoma was evaluated to validate TFE3 expression and survival analysis.
|
29968390 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report a case of a 44-year-old man who has been treated with everolimus for a Xp11.2 translocation/TFE3 gene-fusion RCC after 2 previous failed treatments with tyrosine kinase inhibitor.
|
29702156 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is the first time to correlate the MED15-TFE3 renal cell carcinoma with specific clinicopathologic features.
|
29713041 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Metastatic TFE3-overexpressing renal clear cell carcinoma with dense granules: a histological, immunohistochemical, and ultrastructural study.
|
30040522 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature.
|
29901594 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two transcription factors in this family have been identified in two unusual types of renal cell carcinoma (RCC): Xp11 translocation RCC harbouring TFE3 gene fusions and t(6;11) RCC harbouring a MALAT1-TFEB gene fusion.
|
29148086 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cyto-histological correlation of Xp11.2 translocation/TFE3 gene fusion associated renal cell carcinoma: Report of a case with review of literature.
|
29024535 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
|
29890986 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein, we examined 5 additional cases of SFPQ-TFE3 RCCs using clinicopathologic, immunohistochemical, and molecular analyses.
|
28315422 |
2017 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the frequency of translocation renal cell carcinoma (RCC) by reverse transcription polymerase chain reaction (RT-PCR) and how well the TFE3 immunoreactivity is concordant with TFE3 gene translocation status proved by fluorescence in situ hybridization (FISH) assay and RT-PCR.
|
28415646 |
2017 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
All 7 PRCC-TFE3 RCCs showed positive cathepsin K immunoreactivity.
|
28949976 |
2017 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic studies confirmed the diagnosis of Xp11.2 translocation-associated RCC with positive TFE3 gene rearrangement.
|
28877071 |
2017 |